by | Jul 25, 2025 | Lupus Foundation of America, News & Events
A new study found an association between hydroxychloroquine (HCQ) use and early and long-term benefits on kidney function in people with lupus nephritis, (LN, lupus-related kidney disease). HCQ (known commercially as Plaquenil®) is safe and widely used to support more...
by | Jul 24, 2025 | Lupus Foundation of America
The Lupus Foundation of America (LFA) and Lupus Canada are pleased to announce Mohamed Osman, MD, PhD, Associate Professor of Rheumatology at University of Alberta, as the recipient of the 2025 Lupus Canada Catalyst Award. His study “Defining the molecular drivers of...
by | Jul 24, 2025 | Lupus Foundation of America, News & Events
A recent dual-cohort study has found that Lupus Low Disease Activity State (LLDAS) is an attainable and effective treatment target for people with lupus nephritis (LN, lupus-related kidney disease). LN affects 50-60% of those with systemic lupus erythematosus (SLE)...
by | Jul 22, 2025 | Lupus Foundation of America, News & Events
A new study found a high prevalence of chronic kidney disease (CKD) among people with systemic lupus erythematosus (SLE), including in people without a diagnosis of lupus nephritis (LN, lupus-related kidney disease). In addition, individuals with both lupus and CKD...
by | Jul 21, 2025 | Lupus Foundation of America
The 340B Drug Pricing Program was started in 1992 by Congress to help offset the costs of providing medications to low-income patients by allowing certain hospitals to purchase prescription drugs at significantly discounted prices. Over the past 15 years the program...
by | Jul 3, 2025 | Lupus Foundation of America
Today, the House of Representatives passed H.R. 1, the One Big Beautiful Bill Act, and sent the legislation to the President for his signature. “We are disappointed that members of Congress failed to remove the significant cuts to Medicaid funding included in this...
